Statistiche di base
| CIK | 1109196 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 19, 2019 |
MBVX / MabVax Therapeutics Holdings, Inc. RW - - RW RW 1 mbvxrw.htm RW September 19, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: MabVax Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed November 20, 2018 File No. 333- 228497 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), |
|
| May 9, 2019 |
EX-99.2 • Exhibit 2 • POWER OF ATTORNEY The undersigned hereby constitutes and appoints Steven D. Rubin, with full power to act singly, his true and lawful attorney-in-fact to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a general partner of any partnership or |
|
| May 9, 2019 |
MBVX / MabVax Therapeutics Holdings, Inc. / Opko Health, Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 4)* Under the Securities Exchange Act of 1934 MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Titles of Class of Securities) 55414P702 (CUSIP Number) May 9, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| May 9, 2019 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13G (including amendments thereto) with respect to Mabvax Therapeutics Hol |
|
| April 24, 2019 |
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed; and is indicated with brackets where the information has been omitted from the filed version of this exhibit. |
|
| April 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A Amendment No. 2 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER: 001-378 |
|
| March 29, 2019 |
MBVX / MabVax Therapeutics Holdings, Inc. 15-12G OMB Approval OMB Number: 3235-0167 Expires: May 31, 2021 Estimated average burden hours per response 1. |
|
| March 29, 2019 |
Quarterly Report - AMENDMENT NO. 1 10-Q/A 1 mbvx10qasep302018.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION P |
|
| March 29, 2019 |
CONFIDENTIAL TREATMENT REQUESTED ASSET PURCHASE AND LICENSE AGREEMENT by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH and MABVAX THERAPEUTICS HOLDINGS, INC. |
|
| March 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2019 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation) ( |
|
| January 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2019 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation) |
|
| January 4, 2019 |
Exhibit 99.1 MabVax Therapeutics and Oncotelic Enter into Merger Discussions Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue SAN DIEGO (January 4, 2019) – MabVax Therapeutics Holdings, Inc. (OTC Pink: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery platform focused on the clinical development of products to add |
|
| November 20, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on November 20, 2018 Registration No. |
|
| November 20, 2018 |
Exhibit 10.3 November 19, 2018 MABVAX THERAPEUTICS HOLDINGS, INC., Triton Funds was founded by three undergraduate students from the University of California, San Diego and California State University, Northridge. Our journey started with a simple conversation amongst ourselves about possible careers available to us in the finance field. We concluded that our schools were not target universities f |
|
| November 20, 2018 |
EX-10.1 2 ex10-1.htm EQUITY PURCHASE AGREEMENT WITH TRITON FUNDS LP Exhibit 10.1 EQUITY PURCHASE AGREEMENT This Equity Purchase Agreement (this “Agreement”) is entered into as of November 19, 2018 (the “Execution Date”), by and between MABVAX THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). WHEREAS, the parti |
|
| November 20, 2018 |
EX-10.2 3 ex10-2.htm REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 19, 2018, by and between MABVAX THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (together with it permitted assigns, the “Buyer”). Capitalized terms used herein a |
|
| November 20, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation |
|
| November 13, 2018 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 mbvx10q09302018.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMI |
|
| November 13, 2018 |
EX-10.1 2 ex10-1.htm ASSET PURCHASE AND LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTED Exhibit 10.1 ASSET PURCHASE AND LICENSE AGREEMENT by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH and MABVAX THERAPEUTICS HOLDINGS, INC. and MABVAX THERAPEUTICS, INC. BII Contract No: [***] Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Se |
|
| October 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 22, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation) |
|
| October 20, 2018 |
EX-99.1 2 ex99-1.htm PRESENTATION Exhibit 99.1 |
|
| October 16, 2018 |
MabVax Therapeutics Audited Financial Statements Reinstated Exhibit 99.1 MabVax Therapeutics Audited Financial Statements Reinstated San Diego, CA, October 16, 2018 – MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs, announces today that the Company’s audited financial statements for 2017 |
|
| October 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation) |
|
| October 15, 2018 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE EXHIBIT 4.2 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MABVAX THERAPEUTICS HOLDINGS, INC. ))) C.A. No. 2018-0549-TMR FORM OF ORDER VALIDATING Petitioner’s Corporate Acts Under 8 Del. C. § 205 WHEREAS, Petitioner MabVax Therapeutics Holdings, Inc. (“MabVax”) has filed a Verified Petition for Relief under 8 Del. C. § 205 (the “Petition”) seeking to have this Court validate certain corpo |
|
| October 15, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. QUARTERLY REPORT (Quarterly Report) 10-Q 1 mbvx10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NU |
|
| October 15, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. QUARTERLY REPORT (Quarterly Report) 10-Q 1 mbvx10qmar312018.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSI |
|
| October 15, 2018 |
CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.7 MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Suite 400 San Diego, CA 92121 June 27, 2018 Memorial Sloan-Kettering Institute for Cancer Research 1275 York Ave. New York, NY 10065 Re: Side Letter Agreement to the Exclusive License Agreement, dated June 30, 2008 and amended on May 11, 2011, between MabVax Therapeutics Holdings, Inc. (“Ma |
|
| October 15, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to . Commission file number: 001-37861 MABVA |
|
| October 15, 2018 |
Asset Purchase and License Agreement EX-10.8 5 mbvxex108.htm EXHIBIT 10.8 EXHIBIT 10.8 CONSENT UNDER AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT UNDER AND SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 3, 2018 (the “Second Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexan |
|
| October 15, 2018 |
EX-10.6 3 mbvxex106.htm EXHIBIT 10.6 CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 10.6 SUBLICENSE AGREEMENT This Sublicense Agreement (the “Agreement”) is made and signed as of June 27, 2018 (the “Effective Date”) by and between MabVax Therapeutics Holdings, Inc., with a principal place of business at 11535 Sorrento Valley Road, Suite 400, San Diego, CA 92121 (“MabVax”), on the one hand, and Y-mAbs Th |
|
| August 6, 2018 |
AGREEMENT TO FILE JOINT SCHEDULE 13G EX-99.1 2 ex99-1.htm Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics Hold |
|
| August 6, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Honig Barry C Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Tit |
|
| July 25, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Stetson John Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 554 |
|
| July 25, 2018 |
Joint Filing Agreement with HS Contrarian Investments, LLC Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics Holdings, Inc., a Delawar |
|
| July 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37861 93-0987903 (State or other jurisdiction of incorporation) (Co |
|
| July 9, 2018 |
EX-99 2 ex99-07092018080703.htm Exhibit 99.1 MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers SAN DIEGO, CA – July 9, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announ |
|
| July 5, 2018 |
MabVax Therapeutics Receives Nasdaq Delist Determination Exhibit 99.1 MabVax Therapeutics Receives Nasdaq Delist Determination San Diego, CA, July 5, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company’s |
|
| July 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (Co |
|
| July 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| July 3, 2018 |
EX-99.1 2 ex99-1.htm ADDITIONAL EXHIBITS Exhibit 99.1 MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine SAN DIEGO, CA – July 3, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a privately held clinical stage biopharmaceutical company, an exc |
|
| July 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-37861 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| July 2, 2018 |
MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards Exhibit 99.1 MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards San Diego, CA, July 2, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced |
|
| June 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-37861 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| June 27, 2018 |
MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q San Diego, CA, June 27, 2018 –MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treat |
|
| May 24, 2018 |
8-K 1 mbvx8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-37861 93-0987903 (State or other ju |
|
| May 24, 2018 |
MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q Exhibit 99.1 MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q San Diego, CA, May 24, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that, as expected, t |
|
| May 22, 2018 |
EX-16.1 2 ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 May 21, 2018 Securities and Exchange Commission Washington, D.C. 20549 Dear Sirs: We have read the statements made by MabVax Therapeutics Holdings, Inc. in Item 8.01 of its Current Report on Form 8-K. We agree with such statements as they relate to our Firm. We have no basis to agree or disagree with the other statements made therein. Very truly yours |
|
| May 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-37861 93-0987903 (State or other jurisdiction of incorporation) ( |
|
| May 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. NT 10-Q NT 10-Q 1 form12b25-05142018050501.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-37861 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N- |
|
| May 3, 2018 |
MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering SAN DIEGO, May 3, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced it has entered into securities purchase agreements with accredited inve |
|
| May 3, 2018 |
EX-10.3 7 ex10-3.htm FORM OF MAY 2018 LETTER AGREEMENT Exhibit 10.3 MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Rd., Suite 400 San Diego, CA 92121 Phone: (858) 259-9405 April 26, 2018 Re: Letter Agreement MabVax Therapeutics Holdings, Inc. (the “Company”) and the undersigned hereby agree pursuant to this agreement (this “April 2018 Letter Agreement”) that: A. April 2018 Inducement Sha |
|
| May 3, 2018 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES N CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do |
|
| May 3, 2018 |
Exhibit 3.3 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES O CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of MABVAX THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Corporation”), DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation on April 26, 2018; WHEREAS, the Board of Dir |
|
| May 3, 2018 |
EX-10.1 5 ex10-1.htm FORM OF PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2018 between MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, th |
|
| May 3, 2018 |
Exhibit 3.2 CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES N CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. A Delaware Corporation MabVax Therapeutics Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), in accordance with the provisions of Section 103 t |
|
| May 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) ( |
|
| May 3, 2018 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of May , 2018, among MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) and the investor signatory hereto (the “Investor”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement (as defined below). R E C I T A |
|
| May 3, 2018 |
Exhibit 99.1 |
|
| May 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (Com |
|
| April 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) ( |
|
| April 18, 2018 |
Exhibit 99.1 MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting - Interim results from Phase 1 clinical trial of MVT-1075, demonstrated a dosing strategy for the clinical translation of a radioimmunotherapy product for the treatment of patients with relapsed / refractory pancreatic and other CA19-9 pos |
|
| April 13, 2018 |
Exhibit 99.1 MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq’s Minimum Stockholders’ Equity Requirements - No immediate effect on the Company's Nasdaq listing or the trading of its common stock - SAN DIEGO, CA (April 13, 2018) – MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that it received a lette |
|
| April 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) ( |
|
| April 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| April 2, 2018 |
Exhibit 99.1 MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones – 2017 marked by clinical advancement of treatments for various cancers - – Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 – – Company expects to complete one or more strategic transactions with third parties that are intended to unlock signi |
|
| April 2, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to . Commission file number: 0-31265 MABVAX THERAPEUTICS HOLDI |
|
| March 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| March 6, 2018 |
MabVax Therapeutics Regains Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement Exhibit 99.1 MabVax Therapeutics Regains Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement SAN DIEGO, March 6, 2018 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that it received a letter from the Listi |
|
| March 2, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Hansen John David - SCHEDULE 13D Activist Investment SC 13D 1 mbvxsch13dnov92017.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 55414P |
|
| March 2, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Hansen John David - SCHEDULE 13D/A Activist Investment SC 13D/A 1 mbvxsc13dajan162018.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Cl |
|
| February 28, 2018 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers – Safety results in first cohort enable patient enrollment in second cohort at increased dose – – Tumor target specificity and accumulation of radiolabeled antibody demonstrated i |
|
| February 28, 2018 |
8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporat |
|
| February 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation |
|
| February 16, 2018 |
Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics Holdings, Inc., a Delawar |
|
| February 16, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Honig Barry C Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No. |
|
| February 15, 2018 |
Exhibit 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MABVAX THERAPEUTICS HOLDINGS, INC. MabVax Therapeutics Holdings, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The name of the Corporation is MabVax Therapeutics Holdings, Inc. T |
|
| February 15, 2018 |
Ex99-1 Exhibit 99.1 MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ?s $1.00 Minimum Bid Price Maintenance Requirement San Diego, CA, February 15, 2018 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) (?MabVax? or the ?Company?), a clinical-stage biotechnology company focused on the development of antibody-based products to address |
|
| February 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation |
|
| February 13, 2018 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics Hold |
|
| February 13, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Honig Barry C Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MABVAX THERAPEUTICS HOLDINGS, INC. |
|
| February 12, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) |
|
| February 12, 2018 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer ● All treated patients had measurable tumor reductions ● Promising early results merit additional enrollment ● Company aiming to establish the potential of combination of MVT-58 |
|
| February 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation |
|
| February 12, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of inc |
|
| February 12, 2018 |
Untitled Document Exhibit 99.1 |
|
| February 12, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. / Stetson John Activist Investment SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 55414P 504 (CUSIP Number) |
|
| February 12, 2018 |
Joint Filing Agreement with HS Contrarian Investments, LLC Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics, Holdings, Inc., a Delawa |
|
| February 6, 2018 |
MabVax Therapeutics Closes $2.1 Million Private Placement Financing Ex 99-1 Exhibit 99.1 MabVax Therapeutics Closes $2.1 Million Private Placement Financing SAN DIEGO (February 6, 2018) ? MabVax Therapeutics Holdings, Inc. (the ?Company?) (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of a private financing for a tota |
|
| February 6, 2018 |
8-K 1 mbvx8kfeb22018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State |
|
| February 6, 2018 |
FORM OF COMMON STOCK PURCHASE WARRANT MABVAX THERAPEUTICS HOLDINGS, INC. Ex4-1 Exhibit 4.1 For U.S. Persons: [NEITHER] THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGL |
|
| February 6, 2018 |
Ex 10-2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of January , 2018, among MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?) and the investor signatory hereto (the ?Investor?). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement (as defined below). |
|
| February 6, 2018 |
Exhibit 3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, POWERS, PREFERENCES, PRIVILEGES AND RESTRICTIONS OF THE 0% SERIES M CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, David J. Hansen, hereby certify that I am the Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the ?Company?), a corporation organized and existing under the Delaware General Corporation |
|
| February 6, 2018 |
Ex 10-1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January , 2018 between MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). PREAMBLE WHEREA |
|
| February 2, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. RW WD Untitled Document February 2, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 2, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. RW WD RW WD 1 mbvxcorrespfeb022018.htm RW WD February 2, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: MabVax Therapeutics Holdings, Inc. Registration Statement on Form S-3 Filed October 19, 2017 File No. 333- 221026 Registration Statement on Form S-3 Filed October 25, 2017 File No. 333- 221114 Ladies and Gentlemen: MabVax |
|
| January 31, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 30, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. RW RW January 30, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 30, 2018 |
MBVX / MabVax Therapeutics Holdings, Inc. RW RW January 30, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 30, 2018 |
8-K 1 mbvx8kjan302018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (Stat |
|
| January 30, 2018 |
MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements Blueprint Exhibit 99.1 MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements San Diego, January 30, 2018 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) (?MabVax? or the ?Company?), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that |
|
| January 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on January 18, 2018 Registration No. |
|
| January 16, 2018 |
Blueprint Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update ? Company makes solid progress in advancing discussions with multiple third parties in the evaluation of strategic options that are expected to unlock significant value ? ? Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 ? SAN DIEGO, January 16, 2018 |
|
| January 16, 2018 |
8-K 1 mbvx8kjan162018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2018 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (Stat |
|
| January 16, 2018 |
As filed with the Securities and Exchange Commission on January 16, 2018 Registration No. |
|
| December 21, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. CURRENT REPORT (Current Report) 8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporat |
|
| December 21, 2017 |
EX-3.1 2 ex3-1.htm CERTIFICATE OF ELIMINATION OF SERIES F, SERIES G, AND SERIES H PREFERRED STOCK Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES F CONVERTIBLE PREFERRED STOCK, SERIES G CONVERTIBLE PREFERRED STOCK, AND SERIES H CONVERTIBLE PREFERRED STOCK, OF MABVAX THERAPEUTICS HOLDINGS, INC. (Pursuant to Section 151 (g) of the Delaware General Corporation Law) MABVAX THERAPEUTICS HOLDINGS, INC. |
|
| December 20, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. REGISTRATION STATEMENT s8 As filed with the Securities and Exchange Commission on December 20, 2017 Registration No. |
|
| December 20, 2017 |
ex99-1 Exhibit 99.1 FIFTH AMENDED AND RESTATED MABVAX THERAPEUTICS HOLDINGS, INC. 2014 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Fifth Amended and Restated MabVax Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan, have the fo |
|
| December 20, 2017 |
8-K 1 mbvx8kdec202017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (Sta |
|
| December 20, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy – Company plans to announce interim safety and RECIST data Q1 2018 – SAN DIEGO, December 20, 2017 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-s |
|
| December 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on December 14, 2017 Registration No. |
|
| December 13, 2017 |
ex99-1 Exhibit 99.1 MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers – Company plans on announcing interim data in Q1 2018 – SAN DIEGO, December 13, 2017 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the dev |
|
| December 13, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. CURRENT REPORT (Current Report) 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporat |
|
| December 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on December 11, 2017 Registration No. |
|
| December 12, 2017 |
Exhibit 10.40 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (the ?Agreement?) made this day of , 201 by and between MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and the undersigned subscriber (the ?Subscriber?), who, for and in consideration of the mutual promises and covenants set forth herein, do hereto agree as follows: 1. Subscription. The Subscriber hereby |
|
| December 1, 2017 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Other Events 8-K 1 mbvx8kdec12017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State |
|
| December 1, 2017 |
MabVax Stockholders Approve Proposals at Special Meeting of Stockholders ex99-1 Exhibit 99.1 MabVax Stockholders Approve Proposals at Special Meeting of Stockholders San Diego, December 1, 2017 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that its stockholders approved all proposals at a Special M |
|
| November 22, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE, DATED NOVEMBER 22, 2017 Exhibit 99.1 MabVax Announces Adjournment of Special Meeting of Stockholders Special Meeting to Resume on Friday, December 1, 2017 San Diego, November 22, 2017 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in t |
|
| November 22, 2017 |
Financial Statements and Exhibits, Other Events 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporat |
|
| November 16, 2017 |
Financial Statements and Exhibits, Other Events Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of inc |
|
| November 16, 2017 |
Blueprint Exhibit 99.1 MabVax Therapeutics Regains Compliance with Nasdaq?s Minimum Stockholders? Equity Listing Requirements SAN DIEGO (November 16, 2017) ? MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it rec |
|
| November 13, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. DEFINITIVE PROXY STATEMENT Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 7, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER: 000-31265 MABVAX THERAPEU |
|
| October 25, 2017 |
MabVax Therapeutics Holdings REGISTRATION STATEMENT ON FORM S-3 S-3 1 mbvxs3oct2017.htm REGISTRATION STATEMENT ON FORM S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 25, 2017 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or |
|
| October 24, 2017 |
MabVax Therapeutics Holdings PRE 14A Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| October 19, 2017 |
MabVax Therapeutics Holdings REGISTRATION STATEMENT ON FORM S-3 Blueprint AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 19, 2017 REGISTRATION NO. |
|
| October 19, 2017 |
MabVax Therapeutics Holdings CURRENT REPORT (Current Report/Significant Event) 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporati |
|
| October 19, 2017 |
Ex 3-1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES L CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the ?Company?), a corporation organized and existing under the Delaware General Corporation Law (the ?DGCL?), and furt |
|
| October 19, 2017 |
EX-3.2 3 ex3-2.htm CERTIFICATE OF CORRECTION TO THE CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES L CONVERTIBLE PREFERRED STOCK Exhibit 3.2 CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES L CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. A Delaware Corporation MabVax Therapeutics Holdings, Inc., a co |
|
| October 19, 2017 |
Ex10-2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of October , 2017, by and among the undersigned corporation (the ?Company?), and each signatory hereto (each, an ?Investor? and collectively, the ?Investors?). R E C I T A L S WHEREAS, the Company and the Investors are parties to the Exchange Agreements (the ?Exchange Agreements?), da |
|
| October 19, 2017 |
EX-10.1 4 ex10-1.htm FORM OF EXCHANGE AGREEMENT Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”), effective as October , 2017, is made by and between MabVax Therapeutics Holdings, Inc., a Delaware corporation (“Company”), and the holder of Exchange Securities (as defined herein) signatory hereto (the “Holder”). WHEREAS, the Holder owns shares of the Company’s Series 1 Conv |
|
| October 11, 2017 |
769,231 Shares of Common Stock Blueprint Filed Pursuant to Rule 424(b)(5) Registration No. 333-219291 Prospectus Supplement (to Prospectus dated July 27, 2017) 769,231 Shares of Common Stock We are offering 769,231 shares of our common stock in this offering to a limited number of accredited investors pursuant to this prospectus supplement and the accompanying prospectus. The shares of common stock are being sold at a price of |
|
| October 11, 2017 |
Blueprint Exhibit 10.1 SUBSCRIPTION AGREEMENT MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Suite 400 San Diego, CA 92121 Ladies and Gentlemen: The undersigned (the ?Investor?) hereby confirms and agrees with you as follows: 1. This Subscription Agreement (this ?Agreement ?) is made as of the date set forth below between MabVax Therapeutics Holdings, Inc., a Delaware corporation ( |
|
| October 11, 2017 |
Financial Statements and Exhibits 8-K 1 mbvx8koct102017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (Stat |
|
| October 11, 2017 |
MabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct Offering EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct Offering SAN DIEGO, October 11, 2017 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it has agreed to |
|
| October 11, 2017 |
MabVax Therapeutics Holdings CURRENT REPORT (Current Report/Significant Event) 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 11, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporati |
|
| October 11, 2017 |
ex99-2 Exhibit 99.2 MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers Company plans to announce topline interim results before year end SAN DIEGO (October 11, 2017) – MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development o |
|
| October 6, 2017 |
MabVax Therapeutics Holdings CURRENT REPORT (Current Report/Significant Event) 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporatio |
|
| October 6, 2017 |
Ex 99-1 Exhibit 99.1 MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders Recent Capital Raises Enable Continued Advancement of Clinical Programs to Key Data Milestones San Diego, October 6, 2017 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs |
|
| October 3, 2017 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 mbvx8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other |
|
| October 3, 2017 |
Blueprint Exhibit 99.1 MabVax Stockholders Approve Proposals at Special Meeting of Stockholders Special Meeting to Resume on Friday, October 6, 2017 to Vote on Remaining Proposal San Diego, October 3, 2017 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment o |
|
| September 28, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Announces Adjournment of Special Meeting of Stockholders Special Meeting to Resume on Monday, October 2, 2017 San Diego, September 28, 2017 - MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, t |
|
| September 28, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 mbvx8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or ot |
|
| September 26, 2017 |
2,016,129 Shares of Common Stock Blueprint Filed Pursuant to Rule 424(b)(5) Registration No. 333-219291 Prospectus Supplement (to Prospectus dated July 27, 2017) 2,016,129 Shares of Common Stock We are offering 2,016,129 shares of our common stock in this offering to a limited number of accredited investors pursuant to this prospectus supplement and the accompanying prospectus. The shares of common stock are being sold at a price |
|
| September 22, 2017 |
MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering EX-99.1 4 ex99-1.htm PRESS RELEASE DATED SEPTEMBER 22, 2017 Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering SAN DIEGO, September 22, 2017 – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today |
|
| September 22, 2017 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits 8-K 1 mbvx8ksep222017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (St |
|
| September 22, 2017 |
Exhibit 10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Suite 400 San Diego, CA 92121 Ladies and Gentlemen: The undersigned (the ?Investor?) hereby confirms and agrees with you as follows: 1. This Subscription Agreement (this ?Agreement ?) is made as of the date set forth below between MabVax Therapeutics Holdings, Inc., a Delaware corporatio |
|
| September 19, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. / Stetson John - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) MABVAX THERAPEUTICS HOLDINGS, INC. |
|
| September 13, 2017 |
4,000,000 Shares of Common Stock Blueprint Filed Pursuant to Rule 424(b)(5) Registration No. 333-219291 Prospectus Supplement (to Prospectus dated July 27, 2017) 4,000,000 Shares of Common Stock We are offering 4,000,000 shares of our common stock in this offering to a limited number of accredited investors pursuant to this prospectus supplement and the accompanying prospectus. The shares of common stock are being sold at a price |
|
| September 13, 2017 |
Blueprint Exhibit 1.1 LAIDLAW & COMPANY (UK) LTD. 546 Fifth Ave 41 Dover Street New York, NY 10036 W1S 4NS London * Member FINRA, SIPC* *Incorporated in England & Wales: Company No. 3870324* September 11, 2017 David Hansen President and CEO MabVax Therapeutics Holdings, Inc 11588 Sorrento Valley Road, Suite 20 San Diego, CA 92121 Attention: David Hansen, President and CEO ENGAGEMENT AGREEMENT Purs |
|
| September 13, 2017 |
MabVax Therapeutics Holdings CURRENT REPORT (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2017 (September 11, 2017) MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or oth |
|
| September 13, 2017 |
Blueprint Exhibit 10.1 SUBSCRIPTION AGREEMENT MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Suite 400 San Diego, CA 92121 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms and agrees with you as follows: 1. This Subscription Agreement (this “Agreement”) is made as of the date set forth below between MabVax Therapeutics Holdings, Inc., a Delaware corporation (t |
|
| September 12, 2017 |
Untitled Document |
|
| September 12, 2017 |
MabVax Therapeutics Holdings CURRENT REPORT (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of inc |
|
| September 12, 2017 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorpor |
|
| September 12, 2017 |
MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering Ex99-1 Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering SAN DIEGO, September 12, 2017 ? MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it has agreed to sell approximately 4.0 |
|
| September 8, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of inc |
|
| September 8, 2017 |
Blueprint Exhibit 99.1 MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives - Review includes full company sale, licensing agreements or asset sale coupled with a reverse merger - SAN DIEGO (September 6, 2017) ? MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery pl |
|
| September 8, 2017 |
8-K 1 mbvx-8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or ot |
|
| September 6, 2017 |
MabVax Therapeutics Holdings DEFINITIVE PROXY STATEMENT DEF 14A 1 mbvxdef14aaug2017.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Us |
|
| August 29, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incor |
|
| August 24, 2017 |
MabVax Therapeutics Holdings PRELIMINARY PROXY STATEMENT PRE 14A 1 mbvxpre14aaug2017.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for U |
|
| August 24, 2017 |
8-K 1 mbvx8kaug242017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State |
|
| August 24, 2017 |
MBVX Presentation |
|
| August 22, 2017 |
8-K 1 mbvx8kaug162017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State |
|
| August 22, 2017 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and Is Engaging an Advisory Bank to Explore Strategic Alternatives -Lead Investor Commits to Invest Additional $1.0M Upon Approval of Various Proposals in a Special Meeting of Stockholders to be Scheduled SAN DIEGO, August 22, 2017 – MabVax Therapeutic |
|
| August 14, 2017 |
MBVX Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-219291 PROSPECTUS SUPPLEMENT (To Prospectus dated July 27, 2017) 3,400 Shares of Series J Convertible Preferred Stock (3,400,000 shares of common stock underlying the Series J Convertible Preferred Stock) We are offering up to 3,400 shares of Series J convertible preferred stock, par value $0.01 per share, which we re |
|
| August 14, 2017 |
Exhibit 3.2 Exhibit 3.2 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES K CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of MABVAX THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the ?Corporation?), DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation on August 11, 2017; WHEREAS, the |
|
| August 14, 2017 |
Exhibit 10-1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 11, 2017, between MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to |
|
| August 14, 2017 |
8-K 1 mbvx8kaug112017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State |
|
| August 14, 2017 |
Exhibit 3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES J CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the ?Company?), a corporation organized and existing under the Delaware General Corporation Law (the ?DGCL?), and |
|
| August 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) |
|
| August 14, 2017 |
MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering Press Release Exhibit 99.1 MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering SAN DIEGO, August 14, 2017 ? MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it has entered into securities purcha |
|
| August 14, 2017 |
EX-10.1 5 ex10-1.htm AUGUST LETTER AGREEMENT DATED AUGUST 9, 2017 Exhibit 10.1 MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Rd., Suite 400 San Diego, CA 92121 Phone: (858) 259-9405 August 9, 2017 HS Contrarian Investments, LLC 68 Fiesta Way Fort Lauderdale, FL 33301 Attn: John Stetson Re: Letter Agreement Dear Mr. Stetson, MabVax Therapeutics Holdings, Inc. (the “Company”) and HS Contr |
|
| August 14, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER: 0-31265 MABVAX THERAPEUTICS HO |
|
| August 8, 2017 |
8-K 1 mbvx8kaug32017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State o |
|
| July 25, 2017 |
MabVax Therapeutics Holdings ESP CORRESP 1 filename1.htm MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Ste. 400 San Diego, CA 92121 July 25, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MabVax Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-219291 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulat |
|
| July 21, 2017 |
MabVax Therapeutics Holdings AMENDMENT NO. 1 TO FORM S-3 S-3/A 1 mbvxs3ajuly2017.htm AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on July 21, 2017 Registration No. 333-219291 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Del |
|
| July 14, 2017 |
As filed with the Securities and Exchange Commission on July 14, 2017 As filed with the Securities and Exchange Commission on July 14, 2017 Registration No. |
|
| July 14, 2017 |
MABVAX THERAPEUTICS HOLDINGS, INC., DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS EX-4.1 2 ex4-1.htm FORM OF SENIOR INDENTURE Exhibit 4.1 MABVAX THERAPEUTICS HOLDINGS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS ARTICLE I DEFINITIONS Section 1.1 Definitions of Terms ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.1 Designation and Terms of Securities Section 2.2 Form o |
|
| July 14, 2017 |
MABVAX THERAPEUTICS HOLDINGS, INC., DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS EX-4.2 3 ex4-2.htm FORM OF SUBORDINATED INDENTURE Exhibit 4.2 MABVAX THERAPEUTICS HOLDINGS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS ARTICLE I DEFINITIONS Section 1.1 Definitions of Terms ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.1 Designation and Terms of Securities Sectio |
|
| July 3, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorp |
|
| June 27, 2017 |
Blueprint Exhibit 99.1 MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers Company expects to report interim results by the end of 2017 SAN DIEGO (June 27, 2017) – MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company with a fully human antibody dis |
|
| June 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (C |
|
| June 23, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorpo |
|
| June 23, 2017 |
Untitled Document |
|
| June 14, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 mbvx8kjune122017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or oth |
|
| June 12, 2017 |
MabVax Therapeutics Holdings AMENDMENT NO. 1 TO FORM S-3 s3-am1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 12, 2017 REGISTRATION NO. |
|
| June 12, 2017 |
MabVax Therapeutics Holdings ESP SEC Correspondence MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Ste. 400 San Diego, CA 92121 June 12, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MabVax Therapeutics Holdings, Inc. Registration Statement on Form S-3 File No. 333-218473 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations |
|
| June 5, 2017 |
SEC Connect Exhibit 99.1 MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting ? Single Agent MVT-5873 Appears Safe and Tolerable at Biologically Active Doses ? ? One-Third of Patients with Advanced Pancreatic Cancer Achieve Stable Disease with a Complete Response Reported ? SAN DIEGO, Califo |
|
| June 5, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorp |
|
| June 2, 2017 |
Consent of Independent Registered Public Accounting Firm SEC Connect Exhibit 3.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement on Form S-3 of MabVax Therapeutics Holdings, Inc., of our report dated March 1, 2017, related to our audit of the consolidated financial statements of MabVax Therapeutics Holdings, Inc., as of December 31, 2016 and 2015 and for the years then e |
|
| June 2, 2017 |
MabVax Therapeutics Holdings REGISTRATION STATEMENT ON FORM S-3 SEC Connect AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 2, 2017 REGISTRATION NO. |
|
| May 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorporation) (Co |
|
| May 26, 2017 |
SEC Connect Exhibit 3.1 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of MABVAX THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Corporation”), DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation on May 24, 2017; WHEREAS, the Bo |
|
| May 22, 2017 |
SEC Connect EXHIBIT 10.4 MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Rd., Suite 400 San Diego, CA 92121 Phone: (858) 259-9405 May 22, 2017 Re: Letter Agreement MabVax Therapeutics Holdings, Inc. (the ?Company?) and the undersigned hereby agree pursuant to this agreement (this ?Letter Agreement?) that: A. Inducement Shares The undersigned, upon delivery to the Company of suitable evide |
|
| May 22, 2017 |
EX-10.3 4 ex10-3.htm FORM OF RESCISSION AGREEMENT EXHIBIT 10.3 RESCISSION AGREEMENT THIS RESCISSION AGREEMENT (the “Agreement”), dated and effective as of May 19, 2017 (the “Effective Date”), is made by and between MabVax Therapeutics Holdings, Inc., a Delaware corporation (“Company”), and the holder of the Company’s Series H Preferred Stock signatory hereto (“Holder”). WHEREAS, pursuant to that c |
|
| May 22, 2017 |
MabVax Therapeutics Holdings FORM 10-Q (Quarterly Report) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER: 0-31265 MABVAX TH |
|
| May 22, 2017 |
HS CONTRARIAN INVESTMENTS, LLC 68 Fiesta Way Fort Lauderdale, FL 33301 EX-10.2 3 ex10-2.htm INVESTOR CONSENT EXHIBIT 10.2 HS CONTRARIAN INVESTMENTS, LLC 68 Fiesta Way Fort Lauderdale, FL 33301 May 18, 2017 MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Rd., Suite 400 San Diego, CA 92121 Attn: J. David Hansen Re: Consent to 2017 Offering Dear Mr. Hansen: Reference is made to the following: (i) that Letter Agreement dated August 16, 2016 (hereinafter referred |
|
| May 22, 2017 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT SEC Connect EXHIBIT 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is made effective as of March 31, 2017 (the ?Amendment Date?) and made, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, ?Oxford |
|
| May 22, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2017 Commission File Number: 000-31265 MabVax Therapeutics Holdings, Inc. |
|
| May 22, 2017 |
MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering Blueprint Exhibit 99.1 MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering SAN DIEGO (May 22, 2017) ?MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of its public offering of common stock and |
|
| May 16, 2017 |
424B4 1 mbvx424b4may2017.htm PROSPECTUS Filed pursuant to Rule 424(b)(4) Under the Securities Act of 1933, as amended Registration No. 333-216016 1,342,858 Shares of Common Stock 1,000,000 Shares of Series G Convertible Preferred Stock Convertible Into 1,000,000 Shares of Common Stock We are offering 1,342,858 shares of our common stock at $1.75 per share and 1,000,000 shares of newly designated 0 |
|
| May 15, 2017 |
MabVax Therapeutics Holdings 0-Q MabVax Therapeutics Holdings, Inc. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-37861 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10 |
|
| May 15, 2017 |
Blueprint Exhibit 1.1 MABVAX THERAPEUTICS HOLDINGS, INC. 1,342,858 Shares of Common Stock 1,000,000 Shares of Series G Convertible Preferred Stock UNDERWRITING AGREEMENT May 15, 2017 Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, Fifth Floor New York, NY 10036 Ladies and Gentlemen: MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditi |
|
| May 15, 2017 |
MabVax Therapeutics Announces $4.1 Million Public Offering SEC Connect Exhibit 99.1 MabVax Therapeutics Announces $4.1 Million Public Offering SAN DIEGO (May 15, 2017) ?MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the pricing of its public offering. The offering consists of 1,342,858 |
|
| May 15, 2017 |
SEC Connect Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES G CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the ?Company?), a corporation organized and existing under the Delaware General Corporation Law (the ?DGCL?), and |
|
| May 15, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorp |
|
| May 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on May 12, 2017 Registration No. |
|
| May 12, 2017 |
MabVax Therapeutics Holdings ESP SEC CONNECT MabVax Therapeutics Holdings, Inc. 11535 Sorrento Valley Road, Ste. 400 San Diego, CA 92121 May 12, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MabVax Therapeutics H oldings, Inc. Registration Statement on Form S-1 File No. 333-216016 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under t |
|
| May 12, 2017 |
MabVax Therapeutics Holdings ESP CORRESP 1 filename1.htm LAIDLAW & COMPANY (UK) LTD. 546 Fifth Avenue, 5th Floor New York, New York 10036 May 12, 2017 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 Re: Mabvax Therapeutics Holdings, Inc. Registration Statement on Form S-1 File No. 333-216016 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U |
|
| May 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 S-1/A 1 mbvxs1a-am5may2017.htm AMENDMENT NO. 5 TO FORM S-1 As filed with the Securities and Exchange Commission on May 10, 2017 Registration No. 333-216016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter |
|
| May 11, 2017 |
MabVax Therapeutics Holdings ESP CORRESP 1 filename1.htm May 11, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: MabVax Therapeutics Holdings, Inc. Amendment No. 5 to Registration Statement on Form S-1 Filed May 11, 2017 File No. 333-216016 Dear Ms. Hayes: Please find below the respon |
|
| May 10, 2017 |
8-K 1 mbvx8kmay102017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other |
|
| May 10, 2017 |
EX-10.1 2 ex10-1.htm FORM OF EXCHANGE AGREEMENT Exhibit 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”), dated as of May [ ], 2017 (the “Effective Date”), is made by and between MabVax Therapeutics Holdings, Inc., a Delaware corporation (“Company”), and the holder of the Company’s Series H Preferred Stock signatory hereto (“Holder”). WHEREAS, pursuant to that certain Subscription |
|
| May 9, 2017 |
Exhibit 3.6 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES G CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the ?Company?), a corporation organized and existing under the Delaware General Corporation Law (the ?DGCL?), and further do |
|
| May 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on May 8, 2017 Registration No. |
|
| May 5, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 S-1/A 1 mbvxs1a-am3apr2017.htm FORM S-1/A As filed with the Securities and Exchange Commission on May 4, 2017 Registration No. 333-216016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 93 |
|
| May 5, 2017 |
EX-3.6 2 ex3-6.htm ARTICLES OF INCORPORATION / BYLAWS Exhibit 3.6 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES G CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the “Company”), a corporation organized and existing under the Delaware |
|
| May 3, 2017 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incorpo |
|
| May 3, 2017 |
SEC Connect Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May [], 2017, between MabVax Therapeutics Holdings, Inc, a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to th |
|
| May 3, 2017 |
EX-3.1 2 ex3-1.htm CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES H CONVERTIBLE PREFERRED STOCK Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE 0% SERIES H CONVERTIBLE PREFERRED STOCK OF MABVAX THERAPEUTICS HOLDINGS, INC. I, J. David Hansen, hereby certify that I am the President and Chief Executive Officer of MabVax Therapeutics Holdings, Inc. (the “Co |
|
| May 3, 2017 |
Blueprint Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this ?Agreement?) is being delivered to the purchaser identified on the signature page to this Agreement (the ?Subscriber?) in connection with its investment in the securities of MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?). The Company is conducting a private placement (the ?Offering?) of up t |
|
| May 3, 2017 |
MabVax Therapeutics Holdings PROXY SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 7, 2017 |
MabVax Therapeutics Holdings PRIMARY DOCUMENT (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incor |
|
| April 7, 2017 |
EX-99.1 2 ex99-1.htm ADDITIONAL EXHIBITS Exhibit 99.1 |
|
| March 31, 2017 |
Untitled Document |
|
| March 31, 2017 |
Mabvax 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of incor |
|
| March 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 S-1/A 1 mbvxs1a-am2mar2017.htm AMENDMENT NO. 2 TO FORM S-1 As filed with the Securities and Exchange Commission on March 29, 2017 Registration No. 333-216016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its chart |
|
| March 29, 2017 |
8-K 1 mbvx8kmar292017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or oth |
|
| March 29, 2017 |
Untitled Document |
|
| March 28, 2017 |
MabVax Therapeutics Holdings ESP SEC Connect March 29, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: MabVax Therapeutics Holdings, Inc. |
|
| March 16, 2017 |
MABVAX THERAPEUTICS HOLDINGS, INC. _______ Shares of Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 MABVAX THERAPEUTICS HOLDINGS, INC. Shares of Common Stock UNDERWRITING AGREEMENT , 2017 Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, Fifth Floor New York, NY 10036 Ladies and Gentlemen: MabVax Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell to Laidlaw & Company (UK) Ltd. (the ?Underwrit |
|
| March 16, 2017 |
Exhibit 3.1 -1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42- -43- -44- -45- -46- -47- -48- -49- -50- -51- -52- -53- -54- -55- -56- -57- -58- -59- -60- -61- -62- -63- -64- -65- -66- -67- -68- -69- -70- -71- -72- -73- -74- -75- -76- -77- -78- -79- -8 |
|
| March 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on March 16, 2017 Registration No. |
|
| March 15, 2017 |
MabVax Therapeutics Holdings ESP CORRESP 1 filename1.htm March 16, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: MabVax Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed February 10, 2017 File No. 333-216016 Dear Ms. Hayes: Please find below responses to certain q |
|
| March 1, 2017 |
MabVax Therapeutics Holdings FORM 10-K (Annual Report) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to . Commission file number: 0-31265 MABVAX THERAP |
|
| February 17, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. / Honig Barry C - PRIMARY DOCUMENT Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) MABVAX THERAPEUTICS HOLDINGS, INC. |
|
| February 13, 2017 |
SEC Connect Exhibit 99.1 |
|
| February 13, 2017 |
8-K 1 mbvx8kfeb132017.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2017 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (S |
|
| February 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on February 10, 2017 Registration No. |
|
| February 3, 2017 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 2, 2017 |
MBVX / MabVax Therapeutics Holdings, Inc. / Brauser Michael - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MABVAX THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 (Title of Class of Securities) 55414P504 (CUSIP Number) January 24, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| December 7, 2016 |
MabVax Therapeutics Holdings FORM 8-K (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2016 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (State or other jurisdiction of inco |
|
| December 7, 2016 |
EX-99.1 2 mbvxex99-1.htm CORPORATE PRESENTATION |
|
| November 14, 2016 |
8-K 1 mdvx8knov142016.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2016 MABVAX THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31265 93-0987903 (S |
|
| November 14, 2016 |
SEC Connect Exhibit 99.1 MabVax Therapeutics Reports Interim Safety and Imaging Results from Phase I Clinical Trials in HuMab-5B1 Antibody Development Programs Sufficient safety established to initiate the evaluation of MVT-5873 as a front-line therapy in combination with a standard of care chemotherapy Safety and proof of concept demonstrated for tumor visualization with MVT-2163. Advancing to op |
|
| November 10, 2016 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 mbvx8knov102016.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2016 Commission File Number: 000-31265 MabVax Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter.) |
|
| November 10, 2016 |
EX-99.1 2 ex99-1.htm PRESS RELEASE OF THE COMPANY DATED NOVEMBER 10, 2016 Exhibit 99.1 MabVax Therapeutics Reports Third Quarter 2016 Financial Results and Schedules Conference Call to Provide Corporate Update On Monday, November 14, 2016 Interim Results of Two Phase I Clinical Trials to be Provided at time of Conference Call SAN DIEGO, November 10, 2016 /PRNewswire/ - MabVax Therapeutics Holdings |
